Key result
Colchicine shows no benefit over placebo for preventing restenosis after coronary angioplasty.
Why the study?
Colchicine had shown promise in preventing restenosis after coronary angioplasty in experimental animal models, but clinical trial data were needed.
Does oral colchicine prevent restenosis in patients undergoing elective coronary angioplasty?
RCT (n=197)
2:1
Does oral colchicine prevent restenosis in patients undergoing elective coronary angioplasty?
Absolute Event Rate: 41% vs 45%
p-value: p=NS
Oral colchicine is ineffective for preventing angiographic restenosis after elective coronary angioplasty.
No takes yet. Share an insight, caveat, or question.
Does not warrant routine colchicine post-angioplasty; challenges translation of antimitogenic benefits from animal models to patients.
O’Keefe et al. (1992) conducted an RCT in restenosis after coronary angioplasty (n=197). colchicine vs. placebo was evaluated on Restenosis in at least one lesion (p=NS). Colchicine was ineffective for preventing restenosis after coronary angioplasty, with 41% of treated patients developing restenosis compared to 45% in the placebo group (p = NS).
Synapse has enriched 3 closely related papers on similar clinical questions. Consider them for comparative context: